

Clinical Trial Protocol

Iranian Registry of Clinical Trials

18 Sep 2026

A clinical trial comparing the effectiveness of probiotics along with standard three drug treatment and standard three drug treatment alone in eradicating *Helicobacter pylori* in dyspeptic patients between 15 and 45 years old with positive fecal antigen

Protocol summary

Study aim

Goal: the comparison of standard *Helicobacter pylori* eradication regimen with and without using probiotics

Design

This study is a randomized clinical trial study. Subjects are told that they will be randomly assigned to one of these two 100-person groups.

Settings and conduct

In this study, which is carried out in the Madras hospital clinic, the control group of the standard treatment that includes antibiotics (amoxicillin 1 gram twice a day and clarithromycin 500 mg twice a day) and pantoprazole 40 mg twice a day and placebo twice a day for two will receive a week. In the control group, in addition to the standard treatment, lactacor is prescribed for two weeks. The outcome in this study is the presence of *Helicobacter pylori*, which is measured by the treatment success index. 4 weeks after the treatment, the amount of bacteria removal is evaluated through stool antigen test in both groups.

Participants/Inclusion and exclusion criteria

Entry criteria: age between 15-40 years; Verbal and written consent; symptoms of dyspepsia; Positive fecal *Helicobacter pylori* antigen test. Exclusion criteria: use of any antibiotic in the last 2 weeks; consumption of pump inhibitor during the last 1 month; History of any proven malignancy and history of receiving *Helicobacter pylori* eradication regimen at any time in the past

Intervention groups

In the test group, in addition to the standard treatment (amoxicillin 1 gram twice a day, clarithromycin 500 mg twice a day, and pantoprazole 40 mg twice a day), Lactobacillus and Bifidobacterium probiotic capsules are used for two weeks. In this study, the control group will receive standard and routine national treatment (amoxicillin 1 gram twice a day and clarithromycin 500

mg twice a day and pantoprazole 40 mg twice a day) along with placebo twice a day for two weeks.

Main outcome variables

Eradication of *Helicobacter pylori* infection

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20221216056834N1**

Registration date: **2023-02-02, 1401/11/13**

Registration timing: **prospective**

Last update: **2023-02-02, 1401/11/13**

Update count: **0**

Registration date

2023-02-02, 1401/11/13

Registrant information

Name

Ramin Talaie

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2207 4100

Email address

r.talaie@sbm.u.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-02-20, 1401/12/01

Expected recruitment end date

2023-06-22, 1402/04/01

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
A clinical trial comparing the effectiveness of probiotics along with standard three drug treatment and standard three drug treatment alone in eradicating Helicobacter pylori in dyspeptic patients between 15 and 45 years old with positive fecal antigen

Public title
The effectiveness of probiotics in eradicating Helicobacter pylori infection of the stomach

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
age between 15-40 years Verbal and written consent symptoms of dyspepsia Positive fecal Helicobacter pylori antigen test.
Exclusion criteria:
use of any antibiotic in the last 2 weeks consumption of pump inhibitor during the last 1 month History of any proven malignancy history of receiving Helicobacter pylori eradication regimen at any time in the past.

Age
From **15 years** old to **45 years** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Care provider
- Investigator

Sample size
Target sample size: **200**

Randomization (investigator's opinion)
Randomized

Randomization description
In this study, people are placed in groups using the block blinding method, so that first blocks of 4 are prepared in the form of AABB, ABAB, ABBA, BBAA, BABA, BAAB, and then these blocks are arranged randomly. And people are assigned to two groups according to A and B, and this work is repeated continuously. The website www.sealedenvelope.com is used to generate a random sequence for block randomization.

Blinding (investigator's opinion)
Double blinded

Blinding description
This study is of double-blind type. Blinding for both the participants and the researcher will be done using the identical appearance of the drugs, which will be done by the drug manufacturing company.

Placebo

Used

Assignment
Parallel

Other design features

Secondary Ids
empty

Ethics committees

1

Ethics committee
Name of ethics committee
Faculty of Medicine - Shahid Beheshti University of Medical Sciences (Research Ethics Committee)
Street address
Tehran - Velenjak - Shahid Beheshti University of Medical Sciences - Faculty of Medicine
City
tehran
Province
Tehran
Postal code
198396941
Approval date
2022-10-18, 1401/07/26
Ethics committee reference number
IR.SBMU.MSP.REC.1401.315

Health conditions studied

1

Description of health condition studied
Helicobacter pylori infection in dyspeptic patients

ICD-10 code
B96.81

ICD-10 code description
Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Primary outcomes

1

Description
Fecal antigen

Timepoint
one month after the end of the intervention

Method of measurement
elisa test

Secondary outcomes

1

Description
Digestive complications

Timepoint

1 month after the end of the intervention
Method of measurement
questionnaire

Intervention groups

1

Description

Control group: allocation of the standard treatment regimen alone (i.e. pentaprazole 40 mg (b.i.d), amoxicillin 1000 mg (b.i.d), clarithromycin 500 mg (b.i.d)) for 14 days along with a capsule similar to the probiotic capsule without any medicinal properties Made by a contracted pharmacist that is given exactly like probiotic capsules for 2 weeks from the start of the standard regimen.

Category

Treatment - Drugs

2

Description

Intervention group: treatment with three standard drugs (i.e., pentaprazole 40 mg (b.i.d), amoxicillin 1000 mg (b.i.d), clarithromycin 500 mg (b.i.d)) for 14 days along with probiotic capsules made by Bio Fermentation Company (Lactocer). Contains lactobacillus acidophilus and bifidobacterium bifidum, given twice a day from the day the treatment starts for up to 2 weeks.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Superspeciality Clinic of Modares Hospital in Tehran

Full name of responsible person

Ramin Talaie

Street address

End of Saadat Abad Street - Intersection of Imam Memorial Highway and Saadat Abad

City

Tehran

Province

Tehran

Postal code

1998734383

Phone

+98 21 23515

Fax

+98 21 2207 4101

Email

modarres@sbmu.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Behrouz Abtahi

Street address

Tehran - Evin - Shahid Shahriari Square - Shahid Beheshti University Research and Technology Vice-Chancellor

City

Tehran

Province

Tehran

Postal code

1983969411

Phone

+98 21 29901

Email

pr-office@sbu.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shahid Beheshti University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Ramin Talaie

Position

Associate Professor

Latest degree

Subspecialist

Other areas of specialty/work

Internal Medicine

Street address

Address: The end of Saadat Abad Street - the intersection of Imam Memorial Highway and Saadat Abad

City

Tehran

Province

Tehran

Postal code

1998734383

Phone
021_23515
Email
r.talaie@sbmu.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Ramin Talaie
Position
Associate Professor
Latest degree
Subspecialist
Other areas of specialty/work
Internal Medicine
Street address
Address: The end of Saadat Abad Street - the intersection of Imam Memorial Highway and Saadat Abad
City
Tehran
Province
Tehran
Postal code
1998734383
Phone
021_23515
Email
modarres@sbmu.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Ramin Talaie
Position
Associate Professor
Latest degree
Subspecialist
Other areas of specialty/work
Internal Medicine
Street address

Address: The end of Saadat Abad Street - the intersection of Imam Memorial Highway and Saadat Abad

City
Tehran
Province
Tehran
Postal code
1998734383
Phone
021_23515
Email
r.talaie@sbmu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

All data is potentially shareable after de-identifying individuals

When the data will become available and for how long

The access period starts 6 months after the results are published

To whom data/document is available

Researchers working in academic and scientific institutions

Under which criteria data/document could be used

Students and researchers can use the data of this study

From where data/document is obtainable

Researchers can contact the author of the study through r.talaie@sbmu.ac.ir to receive data and information.

What processes are involved for a request to access data/document

Researchers can contact the author of the study through r.talaie@sbmu.ac.ir to receive data and information.

Comments